BridgeBio Pharma BBIO 深 滬
等待開盤 11-19 09:30:00 美东时间
65.59
-1.310
-1.96%
華盛通- 最 高66.94
- 今 開65.59
- 成交量 210.31万股
- 最 低 64.34
- 昨 收 66.90
- 總市值 125.28亿
- 52周最高 69.48
- 市盈率 靜 --
- 換手率 1.10%
- 52周最低 25.34
- 委 比 64.97%
- 總股本 1.91亿
- 歷史最高 73.50
- 量 比 1.00
- 振 幅 3.89%
- 歷史最低 4.98
- 每 手 1
- 風險率 10.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BBOT to Participate in Upcoming December Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (BBOT) announced that its leadership team will participate in two investor conferences in December. The first presentation will be at the Piper Sandler 37th Annual Healthcare Conference on December 2 at 2:00 p.m. ET, and the second at the 8th Annual Evercore Healthcare Conference on December 3 at 9:35 a.m. ET. Live webcasts and replays will be available on BBOT’s website. BBOT focuses on advancing novel therapies t...
11-18 21:05
BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
BBOT, a clinical-stage biopharma company focused on RAS and PI3Kα pathway malignancies, reported Q3 2025 financials with $468.3M cash runway, advancing three Phase 1 KRAS and PI3Kα inhibitors.近的数据读出预计2026年，任命新任CFO。季度R&D费用达到3510万美元，管理费用为1410万美元，总净亏损4470万美元。
11-12 21:05
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
Acoramidis reduces all-cause mortality (ACM) by 59% in variant ATTR-CM patients and 69% in those with p.Val142Ile genetic variant compared to placebo, showing significant clinical benefit. Data were published in JAMA Cardiology and presented at the AHA Scientific Sessions 2025.
11-08 15:41
JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $77
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $76 to $77.
11-08 03:41
BridgeBio to Participate in November Investor Conferences
BridgeBio Pharma will host fireside chats at the UBS Global Healthcare Conference on November 10 and the Jefferies Global Healthcare Conference on November 18. more info at investor.bridgebio.com. The company focuses on genetic diseases and has a pipeline from early-stage to advanced clinical trials.
11-04 12:30
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
